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Summary
Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia
(AML). Here we report the identification of a small molecule FLT3 tyrosine kinase inhibitor PKC412, which selectively
induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50  10 nM) by directly inhibiting the tyrosine
kinase. Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that
FLT3 is the target of this drug. Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted
with marrow transduced with a FLT3-ITD-expressing retrovirus. PKC412 is a potent inhibitor of mutant FLT3 and is a
candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.
Introduction Tanaka et al., 1997; Olsson et al., 1996). Many of these mutant
genes have been cloned and shown to cause leukemias in mice,
or to cooperate with other oncogenes to cause leukemia inAcute myelogenous leukemia (AML) is a malignant disorder of
hematopoietic cells characterized by an accumulation of highly various models. Identification of these mutant genes, and eluci-
dation of their function, is of critical importance because theyproliferative blasts blocked in differentiation at various stages.
The disease is maintained by transplantable leukemic stem cells represent potentially ideal therapeutic targets for small molecule
drugs, antibodies, or other agents.capable of substantial self-renewal (Bonnet and Dick, 1997).
Cytogenetics, age, and history of a preleukemic syndrome are The class III receptor tyrosine kinase, FLT3 (Fms-Like Tyro-
sine kinase-3; FLK-2, Fetal Liver Kinase-2; or STK-1, humanmajor prognostic determinants. Allogeneic bone marrow trans-
plant (BMT) has had a significant impact on the disease and Stem Cell Tyrosine Kinase-1) (Rosnet and Birnbaum, 1993), has
a number of features that suggest that it is a particularly goodlong-term survival. However, although the number of young
patients treated with either BMT or aggressive chemotherapy therapeutic target. FLT3 is activated by mutations that have
now been detected in about 30% of all patients with AML.has increased steadily over the last 3 decades, such that cur-
rently, patients under age 60 can anticipate 25%–30% ten-year Two types of activating mutations have been described. Internal
tandem duplications within the juxtamembrane (JM) domain ofsurvival, patients over the age of 60, as well as those with
secondary AML or prior myelodysplastic syndrome, continue FLT3 were first reported in AML in 1996 (Nakao et al., 1996). Five
of 30 patients were found to have tandem, in-frame, duplicationsto do extremely poorly. Remarkably, the major chemotherapy
drugs used during induction therapy, cytosine arabinoside and primarily within exon 11, resulting in duplication of a small seg-
ment of the JM domain. Two patients had small insertions inan anthracycline such as daunorubicin, have not changed in
more than 25 years, although a number of useful new agents addition to duplications. No abnormalities of FLT3 were de-
tected in remission samples. The high frequency of JM domainhave value in patients with relapsed disease.
The majority of patients with AML have genetic mutations mutations has been confirmed in several large studies, with an
overall incidence of about 20%–25% of AMLs, and 5% ofthat result in precursor cells exhibiting either blocked differentia-
tion or accelerated proliferation, or both (Pabst et al., 2001; patients with myelodysplastic syndrome (MDS) (Nakao et al.,
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Acute myelogenous leukemia (AML) is a malignant disorder of hematopoietic cells with an incidence of approximately 5 cases per
100,000 population per year. Although standard chemotherapy or stem cell transplantation can induce remission in most patients,
the disease recurs frequently, and the majority of patients will ultimately die of their disease. The discovery of the oncogenes that
cause AML has led to increasing efforts to define novel, oncogene-targeted therapy. The FLT3 tyrosine kinase inhibitor is mutated
in about 30% of patients. We identify a small molecule inhibitor of FLT3, PKC412, and demonstrate that it is selectively toxic to leukemic
cells expressing mutant FLT3 in cell lines and in murine models of leukemia. Inhibition of FLT3 represents a promising approach to
the treatment of AML.
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Figure 1. PKC412 inhibition of cellular proliferation and viability in Ba/F3-FLT3-ITD cells
A–C: Growth of Ba/F3-FLT3-ITD cells cultured for 24 (A), 48 (B), and 72 (C) hr, respectively, in the presence of increasing concentrations of PKC412, and
either in the presence or absence of IL-3. Parental Ba/F3 cells were similarly treated at the indicated time points for comparison. Data points represent the
average of three independent experiments.
D: Growth of parental Ba/F3-FLT3 cells and Ba/F3-FLT3-D835Y cells cultured for 72 hr in the presence of increasing concentrations of PKC412, the latter
cultured in the presence and absence of IL-3. Data points represent the average of two independent experiments.
1996; Horiike et al., 1997; Rombouts et al., 2000; Kondo et al., 2001). FLT3-ITD and D835 mutations worsen disease-free sur-
vival (Yamamoto et al., 2001).1999; Kiyoi et al., 1999, 1998), but have not been seen in acute
lymphoblastic leukemias (ALLs) unless they are biphenotypic Both types of mutations of FLT3 (FLT3-ITD and FLT3-D835)
result in constitutive activation of FLT3 kinase activity. Expres-(Xu et al., 1999). Expression of the mutant FLT3 gene has gener-
ally been found to be a poor prognostic feature (Kondo et al., sion of either of these mutants in factor-dependent cell lines is
associated with rapid conversion to factor-independent prolifer-1999; Kiyoi et al., 1999; Iwai et al., 1999). Interestingly, deletion
of the wild-type allele or mutation of both FLT3 genes has been ation, enhanced viability, and increased tyrosine phosphoryla-
tion of FLT3 itself and other signaling proteins (Kiyoi et al., 1998;reported in a minority of patients, but may be associated with
even poorer prognosis. Mutations in FLT3 have not been seen Hayakawa et al., 2000). Further, transplantation of murine bone
marrow cells infected with a retrovirus expressing a FLT3-ITDin nonhematopoietic cancers, perhaps because expression of
FLT3 is limited to only a few tissues outside of the blood and mutant results in a rapidly lethal myeloproliferative disease (Kelly
et al., 2002).immune system.
The second type of mutation in FLT3 involves point muta- Overall, these data strongly support the notion that inhibition
of FLT3 could have important therapeutic utility in AML. FLT3tions within the “activation loop” of the kinase (Yamamoto et
al., 2001). These point mutations have been reported in an is commonly mutated, and enhances proliferation and viability
through constitutive activation of the tyrosine kinase. Thus, tyro-additional 7% of AML cases, most often involving an asparagine
(Asp) residue at position 835. This residue is homologous to sine kinase inhibitors that selectively target FLT3 would be antic-
ipated to have potential therapeutic utility.Asp 816 in c-KIT, also known to confer an activated phenotype
when mutated in systemic mastocytosis. In both KIT and FLT3, We report here the identification and characterization of
PKC412, an inhibitor of FLT3, and demonstrate that this agentmutations within the activation loop are believed to change the
conformation of this domain, causing it to adopt an “activated” induces cell cycle arrest and apoptosis of leukemic cells ex-
pressing mutant FLT3, but not cells expressing wild-type FLT3.configuration, resulting in kinase activation. D835 mutations
generally occur independently of FLT-3-ITD (Yamamoto et al., Furthermore, PKC412 was found to have significant ability to
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extend survival of mice with FLT3-ITD-induced leukemia. The a mutant FLT3 receptor in Ba/F3 cells. A different approach was
used to determine if PKC412 also inhibited ligand-dependentresults confirm that FLT3 is potentially an excellent therapeutic
activation of wild-type FLT3 receptors, since the addition oftarget for AML and suggest that PKC412 and similar agents are
FLT3 ligand (FLT3L) did not support proliferation of Ba/F3 cellsworthy of evaluation in clinical trials.
in the absence of IL-3 (data not shown), consistent with previous
observations (Hayakawa et al., 2000). Serum-deprived, Ba/F3-Results
FLT3-WT cells were stimulated for 2 or 10 min, respectively, with
FLT3L in the presence or absence of PKC412. FLT3L stimulatedSelective inhibition of proliferation of Ba/F3-FLT3-ITD
tyrosine phosphorylation in Ba/F3 cells expressing the wild-typecells by PKC412
FLT3 receptor as expected, namely of substrates in the 100A diverse set of small molecule tyrosine kinase inhibitors were
kDa range. This increase in tyrosine phosphorylation was abol-screened for their ability to selectively kill growth factor-inde-
ished by 0.01–1 M PKC412 (Figure 4), indicating that kinasependent Ba/F3-FLT3-ITD cells, without inducing apoptosis in
activity of wild-type FLT3 was also likely to be inhibited byparental, growth factor-dependent Ba/F3 cells. These com-
PKC412.pounds were previously identified in other drug screens at No-
vartis Pharma AG as inhibitors of kinases related to FLT3, such
PKC412 inhibits autophosphorylation of mutant
as PDGFR, c-KIT, c-FMS, and others. One compound,
FLT3 receptors
PKC412, inhibited the proliferation of Ba/F3-FLT3-ITD cells with The results in Figure 1 suggested that FLT3 might directly inhibit
an IC50 (inhibitory concentration, 50%) of less than 10 nM within the tyrosine kinase activity of mutant, and wild-type, FLT3 re-
24–72 hr, and was nontoxic toward parental Ba/F3 cells at ceptors. This was examined directly by determining if PKC412
concentrations up to 100 nM (Figures 1A–1C). Reduced cell could inhibit FLT3 receptor tyrosine autophosphorylation. Like
growth was due to both the induction of apoptosis (Annexin V other class III receptor tyrosine kinases, FLT3 is known to un-
staining, Figure 2A) and cell cycle arrest (Figure 2B). Ba/F3- dergo autophosphorylation in response to ligand activation, and
FLT3-ITD cells could be rescued from the inhibitory effects of both ITD and D835 mutants have high levels of ligand-indepen-
PKC412 by IL-3 (Figures 1A–1C and 2A). After 72 hr of treatment, dent tyrosine phosphorylation. Potent inhibition of FLT3 tyrosine
the IC50 for Ba/F3-FLT3-ITD treated with PKC412 was several phosphorylation was seen in Ba/F3-FLT3-ITD and Ba/F3-FLT3-
orders of magnitude lower than the IC50 for the same cells cul- D835Y cells treated with 0.01–1 M of PKC412 within 15 min,
tured in the presence of IL-3 (Figures 1A–1C). This suggests with no apparent effect on levels of FLT3-ITD or FLT3-D835Y
that PKC412 does not significantly inhibit any kinases in the expression (Figure 5). These results suggest that PKC412 works
signaling pathways used by the IL-3 receptor to support growth either by direct inhibition of FLT3 tyrosine kinase activity, or
or proliferation of Ba/F3 cells. by inhibiting a receptor-associated kinase involved in receptor
PKC412 was also found to inhibit proliferation and viability tyrosine phosphorylation.
of Ba/F3-FLT3-D835Y cells (Figure 1D). As with Ba/F3-FLT3-
PKC412 directly inhibits FLT3 kinase activity in vitroITD cells, the inhibitory effects of PKC412 could be reversed
The ability of PKC412 to inhibit FLT3-catalysed phosphorylationby the addition of IL-3.
was assessed using a tyrosine kinase inhibition assay usingThe effects of PKC412 and STI571 were compared on Ba/
the cytoplasmic kinase domain of FLT3. In this assay, PKC412F3 cell lines expressing either FLT3-ITD or p210BCR/ABL (Fig-
demonstrated an IC50 value of 528 161 nM (n 15), confirmingure 3). PKC412 was only toxic to Ba/F3.p210BCR/ABL cells at
that PKC412 is a direct inhibitor of the FLT3 kinase. The majora concentration of 1 M, a dose significantly higher than that
human metabolite of PKC412, CGP052421 (metabolite M [34])required for the inhibition of the growth of FLT3-ITD or FLT3-
had an IC50 value of 643  79 nM (n  3), whereas STI571 didD835Y-expressing Ba/F3 cells. Further, the effect of 1 M
not have significant activity at concentrations 10,000 nM.PKC412 on BCR/ABL-expressing cells was not specific to BCR/
ABL, as parental Ba/F3 cells were also killed at this concentra-
Effect of PKC412 on Ba/F3-FLT3-ITD cellstion of drug. Approximately 100 more PKC412 was required
overexpressing FLT3to inhibit BCR/ABL-expressing cells than STI571, and PKC412
The results above indicate that PKC412 can directly inhibit thewas toxic to the cells both in the presence and in the absence
kinase activity of both wild-type and mutant FLT3. Further, theof IL-3, whereas STI571 was selectively toxic to BCR/ABL-
cell culture experiments shown in Figure 1 also suggest that
expressing cells cultured only in the absence of IL-3. These inhibition of cell growth is highly correlated with expression of
results are consistent with unpublished in vitro kinase assays mutant FLT3. Since PKC412 is known to inhibit other kinases
indicating that this compound is not an effective inhibitor of as well as FLT3, additional studies were done to determine if
c-ABL kinase. Similarly, the c-ABL-kinase inhibitor STI571 was FLT3 could be confirmed as the most important target of this
not toxic to Ba/F3-FLT3-ITD cells except at a very high dose compound in intact cells. Ba/F3-FLT3-ITD cells were cultured
(10 M), consistent with the previous observation that FLT3 is in the presence of increasing concentrations of PKC412 (up to
not a kinase target of this drug. These results suggest that the 0.04 M) over a span of two months to generate a polyclonal
use of paired Ba/F3 cell lines expressing different oncogenic subline of Ba/F3-FLT3-ITD cells less sensitive to PKC412 (Figure
kinases can be useful in demonstrating the specificity of kinase 6A). In these less sensitive cells, but not in Ba/F3-FLT3-ITD
inhibitors. cells similarly cultured in the absence of PKC412, significant
overexpression of FLT3-ITD protein was observed (Figure 6B).
Inhibition of wild-type FLT3 tyrosine kinase activity and Amplification of the gene encoding a drug target and overex-
mutant FLT3 tyrosine kinase activity by PKC412 pression of the target protein are commonly observed mecha-
The above studies demonstrated that PKC412 was an effective nisms of drug desensitization. For example, we have previously
reported that chronic exposure of Ba/F3-p210BCR/ABL cellsinhibitor of proliferation and viability induced by expression of
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Figure 2. PKC412 induction of apoptosis and cell cycle arrest in Ba/F3-FLT3-ITD cells
A: PKC412 induction of apoptosis in Ba/F3-FLT3-ITD in 24 hr (left vertical panel) and 72 hr (middle vertical panel). Drug effects were reversed with IL-3 at
both time points.
B: PKC412 inhibition of cell cycle progression in Ba/F3-FLT3-ITD cells. Ba/F3-FLT3-ITD cells were treated with DMSO vehicle for 24 hr or PKC412 for 24 hr (right
vertical panel).
to STI571 results in amplification of the BCR/ABL transgene nificance level. Pharmacokinetic analysis in Balb/c mice indi-
cated that q24 hr dosing by oral gavage at 100 mg/kg main-(Weisberg and Griffin, 2000). Here, these results provide strong
support for the notion that FLT3 is the relevant target for PKC412 tained plasma concentrations of PKC412 at or above IC50 levels.
Throughout each trial, any animals with massive splenomegalyin these experiments.
by physical exam (spleen boundary at the dorsal midline) or that
were moribund were sacrificed and analyzed. Data collectedIn vivo inhibition of FLT3-ITD-mediated transformation
by PKC412 included total and differential white blood cell counts, gross
morphological features, and spleen weight (Table 1). OrgansTwo independent trials were performed using a BMT assay to
test the efficacy of PKC412 on the FLT3/ITD-induced myelopro- from all animals were fixed and analyzed for histological features
of disease. The immunophenotype of spleen cells of 4 animalsliferative disorder (MPD) in vivo. We assessed efficacy of
PKC412 in established FLT3-ITD disease to most closely mimic from each group was also analyzed.
Kaplan-Meier analyses for survival (Figures 7A and 7B) oftherapy of established disease in humans. Our previous obser-
vations with the FLT3/ITD BMT assay indicated that disease placebo- and drug-treated mice for each of the two trials dem-
onstrated that PKC412 prolonged survival, with p values ofwas well established at approximately 30 days posttransplant,
and that 90% of animals succumbed to disease by day 90 0.0005 and 0.009 for trials 1 and 2, respectively, using a log
rank analysis. A Kaplan-Meier plot with the combined data from(Kelly et al., 2002). In trial 1, the mice were treated with drug
from day 30 on. In trial 2, drug was administered from day 25 trials 1 and 2 is shown in Figure 7C. Assessment of plasma
PKC412 concentrations was performed at the trial 1 study end-on. Assuming that 20% of drug-treated animals and 80% of
untreated animals would develop MPD, we designed each trial point. Plasma samples were obtained from six mice sacrificed
8–12 hr after dosing, and showed plasma concentrations ofto have 80% power to detect this difference at the 0.05% sig-
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Figure 3. Selectivity of PKC412 for FLT3-expressing cells
A and B: Ba/F3.p210 cells were cultured for 72 hr in the presence and absence of IL-3 with increasing concentrations of STI-571 (A) or PKC412 (B). Ba/F3
cells were similarly treated in each experiment in the presence of IL-3. For each, data points represent the average of two independent experiments.
Parental Ba/F3 cells (cultured in the presence of IL-3) and Ba/F3-FLT3-ITD cells (cultured in the absence of IL-3) were treated for 72 hr with STI-571
C: Data points represent the average of three independent experiments.
545  237 ng/ml (range: 333–379 ng/ml; 545 ng/ml  954 nM),
which were well above the PKC412 IC50 for inhibition of Ba/F3-
FLT3-ITD cells in tissue culture.
Analysis of the data from each trial (Table 1) showed that the
majority of placebo animals developed characteristic features of
FLT3/ITD MPD, while none of those treated with PKC412 did.
The mean spleen weight was 401 mg for placebo animals, corre-
sponding to a 4-fold increase in size compared to irradiated
transplanted controls (100 mg). In contrast, PKC412-treated
mice displayed only a slight increase in mean spleen weight (80
mg). Similarly, the mean white blood cell count for placebo
animals was 25.8 106 /ml compared to 3.6 106 /ml for drug-
treated animals.
Histopathologic examination of the spleen from representa-
tive animals (Figure 8) further supported the interpretation of a
dramatic reduction in FLT3-ITD-induced disease in the drug-
treated mice compared to placebo controls. Splenic architec-
ture was effaced in the placebo mice by a marked expansion
of red pulp comprised of maturing myeloid cells and scatteredFigure 4. Inhibition of wild-type FLT3-mediated cellular tyrosine phosphoryla-
tion by PKC412 admixed megakaryocytes. The spleen displayed marked hyper-
Ba/F3-FLT3 cells were serum-starved overnight and treated for 1 hr with 0.01 cellularity and myeloid hyperplasia consisting predominantly of
M or 1 M PKC412, prior to 2 min or 10 min of FLT3 ligand stimulation, mature granulocytic elements. In contrast, the drug-treated ani-
respectively. Cellular tyrosine phosphorylation was analyzed by immu- mals showed a partial recovery of splenic architecture, a reduc-
noblotting with a pTYR antibody. A -actin antibody was used as a loading
tion in myeloid hyperplasia, and a corresponding increase incontrol. Elevation of tyrosine phosphorylation of bands at approximately
100 kDa is shown (left hand arrow). the proportion of other hematopoietic lineages.
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Figure 5. Inhibition of FLT3-ITD and FLT3-D835Y au-
tophosphorylation by PKC412
FLT3-ITD was immunoprecipitated from Ba/F3-
FLT3-ITD cells treated for 15 min with varying con-
centrations of PKC412. Immunoblotting was per-
formed on all samples with a pTYR antibody (up-
per panel) and a FLT3 antibody (lower panel).
Rabbit serum was used as a control for nonspe-
cific binding of the FLT3 antibody. FLT3-D835Y was
immunoprecipitated from Ba/F3-FLT3-D835Y cells
and treated as for FLT3-ITD.
The immunophenotype of single cell suspensions from the Discussion
spleens of 4 placebo and 4 PKC412-treated animals from trial
The FLT3 receptor tyrosine kinase gene is mutated in approxi-1 was examined using myeloid markers Gr-1 and Mac-1 to
mately one-third of patients with AML. The mutations have beenevaluate the proportion of myeloid cells present. These data
detected in all FAB subtypes of AML in both adult and pediatricshowed that the placebo mice had a profile consistent with
patients, but are rarely detected in either ALL or MDS. The mostclassic FLT3-induced myeloproliferative disease (Kelly et al.,
common mutations result in tandem duplications of a variable2002). In contrast, mice treated with PKC412 had an average
of 5% myeloid cells, which is comparable to a disease-free number of amino acids within the juxtamembrane domain, and
have been reported in approximately 20%–25% of patients (Na-Balb/c mouse (4%) (data not shown).
Figure 6. PKC412 Resistance in Ba/F3-FLT3-ITD cells
A: Proliferation of PKC412-resistant Ba/F3-FLT3-ITD cells in the presence of PKC412. Ba/F3-FLT3-ITD cells cultured for several months in the presence of gradually
increasing concentrations of PKC412 (up to 0.04 M) were treated with PKC412 and compared to Ba/F3-FLT3-ITD cells that had not been previously cultured
in the presence of drug. Data points represent the average of two independent experiments.
B: Overexpression of FLT3-ITD in PKC412-resistant Ba/F3-FLT3-ITD cells. FLT3-ITD was immunoprecipitated from nonresistant and PKC412-resistant Ba/F3-FLT3-
ITD cells and analyzed by immunoblotting with a pTYR antibody and a FLT3 antibody, respectively (left panel). Whole cell protein lysates of nonresistant
and PKC412-resistant Ba/F3-FLT3-ITD cells were analyzed by immunoblotting with a FLT3 antibody (right panel). A -actin antibody was used as a loading
control.
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Table 1. Phenotypic analysis of placebo and PKC412-treated animals
Spleen weight (mg) WBC (106/ml)
Placebo PKC412 Placebo PKC412
Mean 401 80 25.8 3.6
Median 387 83 12 3.2
Range 105–801 61–98 4.0–160.0 0.4–12.0
n 22 13 22 22
p value 3  106 3  106 6  105 6 105
Data are presented for placebo animals and PKC412-treated animals at
trial endpoint. The white blood cell counts and spleen weights are shown
per milliliter (106/ml) and in milligrams (mg), respectively. In each case, the
mean vlaue, the median value, the range, and the number of animals (n)
are listed.
kao et al., 1996; Rombouts et al., 2000; Kondo et al., 1999;
Kiyoi et al., 1997). An additional 7% of patients have point
mutations within the activation loop of the kinase domain, most
often involving asparagine 835 (Yamamoto et al., 2001). The
presence of a mutation has been generally reported to be inde-
pendently associated with a poor prognosis (Yamamoto et al.,
2001).
The mutations result in constitutive activation of the tyrosine
kinase activity of FLT3, autophosphorylation of the receptor,
and tyrosine phosphorylation of a number of signaling molecules
such as STAT5 and SHP2 (Hayakawa et al., 2000; Fenski et al.,
2000). Expression of a mutant receptor in an IL-3-dependent
hematopoietic cell line, such as Ba/F3, induces IL-3-indepen-
dent proliferation. In contrast, cells expressing the wild-type
receptor do not proliferate in the absence of growth factors
without the addition of FLT3 ligand (Dehmel et al., 1996). Trans-
plantation of murine marrow infected with a retrovirus express-
ing FLT3 juxtamembrane domain mutants into irradiated mice
results in a lethal myeloproliferative syndrome, without evidence
of any significant block in differentiation of granulocyte lineage
cells (Kelly et al., 2002). Thus, as is the case with a number of
other tyrosine kinase oncogenes, the major biological effect of
mutant FLT3 receptors may be primarily to induce proliferation
and enhance viability of immature myeloid cells. These mutant
receptors would therefore be likely to cooperate with other AML
oncogenes such as AML1/ETO or PML/RAR 	 that function
primarily to block differentiation, resulting in the production of
an aggressive leukemia. Figure 7. In vivo inhibition of FLT3-ITD-mediated transformation by PKC412
The high incidence of activating mutations of FLT3 has sug- Kaplan-Meier plots of survival.
A and B: Mice transplanted with bone marrow transduced with FLT3-ITDgested that inhibitors of mutant FLT3 might have therapeutic
treated with placebo (n  22) or with PKC412 at 100 mg/kg/day (n  22).activity in AML. Two antagonists of the FLT3 receptor (AG1296
The percentage of surviving mice (y-axis) is plotted with respect to time inand AG1295) have been identified that inhibit FLT3-mediated
days (x-axis). The p values were obtained using the log rank test. The period
transformation and induce apoptosis in cells expressing consti- of drug administration is indicated by the shaded boxes, day 30–88 in Trial
tutively activated FLT3 or primary leukemic blasts from AML 1 (A) and day 25–68 in Trial 2 (B).
C: Combined data from trials 1 and 2.patients harboring FLT3/ITD mutations, respectively (Levis et
al., 2001a; Tse et al., 2001). These compounds were effective
at micromolar concentrations (Levis et al., 2001a, 2001b). Herbi-
mycin A was also found to be effective at killing cells expressing
(O’Farrell et al., 2001). The KDR receptor inhibitors SU5416mutant FLT3 (Zhao et al., 2000). The cytotoxicity of herbimycin
and SU5614 inhibited growth of ITD-FLT3-expressing cells lessA was found to be due to the targeting of Hsp90 (Minami et al.,
potently (IC50  250 nM and 100 nM, respectively) (Yee et al.,2001). Both Herbimycin A and the Hsp90 inhibitor Radicicol
2001). Two novel FLT3 inhibitors, CEP-701 and CEP-5214, havecaused mutant FLT3-transformed 32D cells to selectively un-
been identified, which inhibit FLT3 tyrosine kinase activity indergo apoptosis (Minami et al., 2001). The SUGEN compound
vitro (IC50  1–2 nM) and in vivo, and are antileukemic in anSU11248, which inhibits KDR and PDGF-R, was demonstrated
to inhibit wild-type and ITD-FLT3 receptors (IC50  10 nM) ITD-FLT3 mouse leukemia model (Levis et al., 2001b; Allebach
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growth factor (VEGF) receptor, the platelet derived growth factor
receptor  (PDGFR), and KIT, the receptor for Steel Factor
(35). Thus, the kinases inhibited by PKC412 differ substantially
from those targeted by STI571 (Gleevec, Novartis Pharma),
which inhibits ABL, PDGFR, and KIT, but does not significantly
inhibit FLT3, PKC, or KDR at concentrations below 10 M. In
other preclinical studies, PKC412 inhibited VEGF-dependent
angiogenesis in a growth factor implant model (Fabbro et al.,
2000). Orally administered PKC412 also strongly inhibited retinal
neovascularization and laser-induced choroidal neovasculariza-
tion in murine models (Fabbro et al., 2000). It was also syner-
gistic with ionizing irradiation in animal tumor models, again
thought to be because of its antiangiogenic activities (Fabbro
et al., 2000). In a Phase I trial of patients with solid tumors,
significant nausea, vomiting, and diarrhea developed at the
highest dose tested, 300 mg/kg/day (Propper et al., 2001). Only
two of 32 patients developed myelosuppression. The estimated
median elimination half-life was 1.6 days (range, 0.9 to 4.0 days).
Figure 8. Histopathological analysis of animals treated with PKC412 or pla- Steady-state PKC412 plasma levels at the top three dose co-
cebo at study endpoint horts (150 to 300 mg) were 0.2 to 0.7 mol/L, 20 to 70 times
A (10) and B (50): In placebo-treated animals, splenic architecture was the IC50 for Ba/F3-FLT3-ITD cells in culture. Thus, PKC412 can
effaced by a marked expansion of red pulp comprised of maturing myeloid be safely administered to patients at doses that achieve plasma
cells and scattered admixed megakaryocytes. The spleen displayed char-
levels sufficient to inhibit mutant FLT3 in AML cells.acteristic features of a MPD with marked hypercellularity and myeloid hyper-
Since PKC412 has a number of potential targets, as is theplasia consisting predominantly of mature granulocytic elements.
C (low power) and D (high power): In contrast, the drug-treated animals case for most other tyrosine kinase inhibitors, several ap-
showed a partial recovery of splenic architecture, a reduction in myeloid proaches were taken to determine if FLT3 could be confirmed
hyperplasia, and a corresponding increase in the proportion of other hema-
as the actual target of this inhibitor. First, it was shown thattopoietic lineages.
PKC412 inhibited proliferation of Ba/F3 cells transformed by
mutant FLT3, but not Ba/F3 cells transformed by p210BCR/
ABL (except at concentrations 50–100 higher than those
required to inhibit FLT3). Second, the toxicity of PKC412 foret al., 2001). These preliminary studies suggested that inhibitors
Ba/F3-ITD cells was reversed completely by the addition of IL-3,of FLT3 could have a substantial cytotoxic effect on leukemic
indicating that kinases such as Jak-2 that are known to becells expressing mutant receptors. It seems likely that several
required for IL-3 receptor signaling are not targets of PKC412.of these inhibitors will be tested in clinical trials in AML, and it
Third, PKC412 inhibited tyrosine phosphorylation of FLT3 itselfwill be of interest to compare their efficacy and toxicities. It is
and also inhibited in vitro kinase activity of a purified FLT3quite possible that the non-FLT3 targets of each drug will influ-
kinase domain peptide. Fourth, and perhaps most significant,ence both their efficacy and toxicity; these targets are likely to
prolonged exposure of cells generated in tissue culture to suble-differ significantly.
thal concentrations of PKC412 resulted in a dramatic overex-In this study, we report the identification of PKC412
pression of FLT3. This overexpression of FLT3 resulted in the(N-benzoyl staurosporine) as a highly active inhibitor of both
cells becoming less sensitive to PKC412. Overexpression of amutant and wild-type FLT3 tyrosine kinases, and show that the
drug target is a well-known mechanism of drug desensitization,drug is cytotoxic to both cell lines and primary cells expressing
and we have previously shown, for example, that similar treat-mutant FLT3 receptors. PKC412 was selected in a screen to
ment of Ba/F3p210BCR/ABL cells with STI571 resulted in aidentify compounds that were cytotoxic to Ba/F3 cells express-
similar overexpression of BCR/ABL (Weisberg and Griffin, 2000).ing FLT3-ITD, and was found to inhibit proliferation of both Ba/
For PKC412-resistant cells, a number of mechanisms for theF3-ITD and Ba/F3-D835Y cells with an IC50 of less than 10 nM,
increased protein level must be considered and evaluated, suchwhile the IC50 against Ba/F3 cells expressing p210BCR/ABL or
as gene amplification, increased transcription, and altered transla-Ba/F3 cells growing in IL-3 was 500 nM. PKC412 induced
tion or protein stability. Preliminary studies suggest that both thecell cycle arrest of Ba/F3-ITD cells in less than 24 hr, and apopto-
FLT3 RNA and DNA are increased several fold in PKC412-resistantsis within 24–48 hr. The effects of PKC412 on both proliferation
cells (data not shown). Taken together, these results suggestand viability are consistent with the hypothesis that the major
that FLT3 is directly inhibited by PKC412, and that this is thebiological effects of this activated tyrosine kinase receptor onco-
most critical target of the drug in the cell line Ba/F3-FLT3-ITD.gene are to induce, or amplify, ligand-independent proliferation
To determine if the significant inhibitory effects of PKC412and to prolong viability of myeloid progenitor cells.
against FLT3 observed in tissue culture could be translated toIn keeping with the cellular findings, we have also shown
an animal model of leukemia, mice transplanted with marrowthat PKC412 is a potent inhibitor of FLT3 tyrosine kinase activity
cells transduced with a FLT3-ITD retrovirus were treated dailywith an IC50 value of 530 nM. PKC412 is a synthetic derivative
with PKC412 or vehicle control in two independent trials, startingof the naturally occurring alkaloid staurosporine, and was pre-
32 or 25 days after the transplant, respectively. This model isviously shown to be an inhibitor of protein kinase C (the major
well suited to analysis of efficacy of FLT3 inhibitors in vivotransducer of lipid second messengers and phorbol esters),
KDR, a tyrosine kinase associated with a vascular endothelial because it utilizes primary bone marrow cells, and disease is
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Cell viability, cell cycle, and apoptosis measurementsmediated solely by the FLT3-ITD (Kelly et al., 2002). In previous
Following staining with trypan blue (Sigma, St. Louis, MO), the number ofstudies, mice receiving these transplants were found to develop
viable cells was determined by counting unstained cells with a hemacytome-a myeloproliferative syndrome that was lethal in 30 to 90 days
ter. Cell viability is reported as percentage of control (untreated) cells, and
in 100% of recipients (Kelly et al., 2002). Administration of data are presented as the average of 2–3 independent experiments, as
PKC412 to the mice was not started until 25–32 days after the indicated in the figure legends. Error bars represent the standard error of
the mean for each data point. Apoptosis of drug-treated cells was measuredtransplant, in order to allow time for the mice to develop an
using the Annexin-V-Fluos Staining Kit (Boehringer Mannheim, Indianapolis,aggressive, potentially lethal, leukemia before starting treat-
IN). Briefly, 500,000–1  106 cells cultured in the presence or absence ofment, thereby providing a better model for therapy of human
drug were washed 1with phosphate-buffered saline (PBS) and centrifuged
disease. Remarkably, at the time the study was stopped, all 22 for 5 min at 1500 rpm. Washed cell pellets were resuspended in 100 l of
mice in the control arms had developed fatal MPD, while none 20% Annexin-V-fluorescein labeling reagent and 20% propidium iodide (PI)
of 22 mice treated with PKC412 had either developed visible in HEPES buffer. Cells were incubated for 15 min at room temperature,
followed by dilution with 0.8 ml of HEPES buffer. Samples were then analyzedsigns of leukemia or expired. Further, spleen weights and blood
by flow cytometry. As controls, cells were incubated for 15 min with PI alone,leukocyte counts were significantly lower in mice treated with
Annexin-V-fluorescein labeling reagent alone, or HEPES buffer, and thenPKC412 at the end of the studies, compared to mice receiving
diluted with HEPES buffer and analyzed by flow cytometry.
control. Serum samples taken at the termination of the first Cell cycle analysis was performed using approximately 500,000 cells,
study from six representative animals had levels of PKC412 (or which were centrifuged at 1500 rpm for 5 min, washed in PBS, and the
the predominant metabolite CGP052421) of 545  237 ng/ml pellet resuspended in 500 l of propidium iodide solution (50 g/ml propid-
ium iodide, 0.1% NP-40, 0.1% sodium citrate). The mixture was stored in(range 333–879 ng/ml; 545 ng/ml  954 nM), about 100-fold
the dark at 4
C for a minimum of 15 min, and then analyzed by flow cytometry.higher than the IC50 for Ba/F3-FLT3-ITD cells in tissue culture.
As the mice tolerated these high serum levels of PKC412 for
Antibodies
60 days without overt signs of toxicity, these results suggest Anti-pTyr, monoclonal antibody (mAb) #4G10, was a gift from Dr. Brian
there is a substantial therapeutic window in vivo. Druker, University of Oregon Health Sciences Center (Portland, OR) and was
Overall, the results presented here strongly support the no- diluted 1:2500 for use in immunoblotting. FLT3/Flk-2 (C-20) was purchased
from Santa Cruz Biotechnology, Inc., and used at 1:200 for immunoblotting.tion that FLT3 is potentially a good drug target in AML. FLT3
Monoclonal anti--actin (Clone AC-15) was purchased from Sigma and di-is frequently mutated, and both types of known mutations are
luted 1:1000 for immunoblot.inhibited by PKC412 at nanomolar concentrations in culture.
Further, PKC412 causes extensive and rapid apoptosis of FLT3-
Immunoprecipitation and immunoblotting
expressing cells, a desirable feature for a potential antileukemic Cells were lysed in lysis buffer (0.02 M Tris [pH 8.0], 0.15 M NaCl, 10%
drug. Finally, the significant effects in an animal model of leuke- glycerol, 1% NP-40 (wt/vol), 0.1 M NaF, 1 mM phenylmethylsulfonyl fluoride,
1 mM sodium orthovanadate, 40 g/ml leupeptin, and 20 g/ml aprotinin).mia suggest that the in vitro activity can also be observed in
Protein lysates were incubated for 25 min on ice, with vortexing at 5 minvivo. It will be of considerable interest to determine whether
intervals, and then centrifuged for 15 min at 12,000  g. Supernatants wereFLT3 can be successfully inhibited in leukemic cells upon treat-
saved, and the Bio-Rad Protein Assay was used to determine protein yieldsment of AML patients in vivo, and if this has a beneficial thera-
(Bio-Rad Laboratories, Hercules, CA). Equivalent amounts of protein were
peutic effect. subsequently loaded directly onto a gel for immunoblotting experiments.
For immunoprecipitation, cell lysates were incubated with FLT3/Flk-2 (C-20)
Experimental procedures antibody and protein A Sepharose overnight with rocking at 4
C. As a control,
cell lysates were also incubated with protein A Sepharose beads alone.
Cell lines and cell culture Following incubation, immune complexes were washed 2 with lysis buffer,
The IL-3-dependent murine hematopoietic cell line Ba/F3 was transduced 2 with 1 PBS, and were dissolved in Laemmeli’s sample buffer by boiling
with either wild-type FLT3-, FLT3-ITD-, or FLT3-D835Y-containing MSCV for 5 min. For immunoblotting and immunoprecipitation, whole cell lysates
retroviruses harboring a neomycin selectable marker, and selected for resis- and immune complexes, respectively, were resolved on a sodium dodecyl
tance to neomycin (Kelly et al., 2002). FLT3-ITD transduced cells were se- sulfate (SDS)-7.5% polyacrylamide gel. Following this, protein was electro-
lected for growth in G418 (1 mg/ml). Expression of FLT3 or mutant FLT3 was phoretically transferred to a Protran nitrocellulose transfer and immobilization
documented by flow cytometry and Western blot with anti-FLT3 antibody. membrane (Schleicher and Schuell, Dassel, Germany). The membrane was
Polyclonal Ba/F3 cell lines expressing wild-type, FLT3-ITD, or FLT3-D835Y then blocked overnight at 4
C with 5% nonfat dry milk in 1 TBS (10 mM
are termed Ba/F3-FLT3-WT, -FLT3-ITD, and -FLT3-D835Y, respectively. Ba/ Tris-HCl [pH 8.0], 150 mM NaCl) and then probed for 2 hr at 25
C with pTYR
F3-FLT3-ITD and Ba/F3-FLT3-D835Y could proliferate independently of IL-3, antibody or overnight at 4
C with FLT3/Flk-2 (C-20) antibody in 1 TBST
while parental cells and Ba/F3-FLT3-WT remained factor dependent. All cell buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween20). Following
lines were maintained in the presence of 10% WEHI-conditioned medium 3 washes with 1 TBST, membranes were incubated for 1 hr at 25
C with
as a source of IL-3 to reduce the likelihood of any line acquiring additional anti-mouse immunoglobulin (horseradish peroxidase-linked whole antibody
mutations. IL-3 was removed from media prior to experimentation. Ba/F3 from sheep) or anti-rabbit immunoglobulin (horseradish peroxidase linked
cells expressing p210BCR/ABL have been previously described (Daley and whole antibody from donkey) (Amersham Life Science, Inc., Arlington
Baltimore, 1988; Sattler et al., 1996; Okuda et al., 1996). All cell lines were Heights, IL). The membrane was washed 5 in 1 TBST buffer, with 5 min
cultured at 37
C with 5% CO2 at a concentration of 2  105 to 5  105 in intervals between buffer changes, and bound antibodies were detected with
RPMI (Mediatech, Inc, Herndon, VA) with 10% fetal calf serum and supple- enhanced luminol and oxidizing reagent as specified by the manufacturer
mented with 1% glutamine. (NEN Life Science Products, Boston, MA). Bound antibodies were removed
with stripping buffer (2% SDS, 0.0625 mol/L Tris [pH 6.8], and 0.7%
Chemical compounds and biologic reagents 2-mercaptoethanol) 50
C for 30 min. The filter was then probed with addi-
PKC412 and STI571 (Gleevec, Glivec) were obtained from Novartis Pharma tional antibodies.
AG, Basel, Switzerland, and dissolved in DMSO to make an initial stock
solution. Serial dilutions were then made, also in DMSO, to obtain final Development of PKC412 resistant Ba/F3-FLT3-ITD cell lines
dilutions for cellular assays. FLT3 ligand (PeproTech, Inc., Rocky Hill, NJ) Ba/F3-FLT3-ITD cells were cultured in the presence of increasing concentra-
was added to some cell cultures at a concentration of 100 ng/ml for up to tions of PKC412 (0.01 M to 0.04 M) over a period of approximately two
months. Cells were initially cultured in the presence of 0.01 M PKC412,10 min.
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with culture medium changes every 6–7 days, for a total of 28 days. Cells PKC412 concentration of 12.0 mg/ml. The animals were weighed prior to
were then cultured in 0.02 M PKC412 for an additional 25 days, and finally treatment, and every 7 days thereafter, to ensure that a consistent dose
cells were transferred to media containing 0.04 M PKC412. Surviving cells (100 mg/kg/day) of drug was administered. Dosing was performed every 24
continued to be passaged thereafter in the presence of 0.04 M PKC412, hr by gavage of a maximum volume of 150 l per animal using 22 gauge
and were analyzed for resistance to the drug. gavage needles (Hornbecks). Placebo animals received the same volume of
a Gelucire 44/14 and water solution prepared in the same way as described
In vitro kinase assay above for the PKC412/Gelucire mixture.
The coding sequence of the cytoplasmic kinase domain of human FLT3 (aa Statistical analysis and study design
563–993) was amplified by PCR from human cDNA libraries (Clontech) and In each trial, mice were dosed with either drug or placebo. In comparing
cloned into pFbacG01 vector made compatible for ligation by digestion with the survival time of the mice, all times were measured from the day of BMT,
BamH1 and HindIII resulting in a cDNA carrying N-terminal GST fused in and the log rank test was used to attach a significance level to the difference
frame to the cytoplasmic kinase domain of FLT3 (pFbacG01-GST-FLT3). To in the survival curves. Mice who remained alive at the end of the study or
generate viral DNA, the pFbacG01-GST-FLT3 was transfected into who were sacrificed in an apparently healthy condition at the end of the
DHC10Bac (GIBCO). DNA from positive colonies was transfected into either study were considered censored in this analysis.
Sf9 or Sf21 cells (American Type Culture Collection) using Cellfectin (GIBCO) Gross morphological analysis
reagent (Homann et al., 2001). Mice were examined for splenomegaly every 3–4 days by palpation of the
Recombinant baculovirus was collected from the transfected cell culture abdomen. Animals with spleens that crossed the dorsal midline were sacri-
and used for infection. After two rounds of infection, the media was used ficed and analyzed. Peripheral blood was collected from the retro-orbital
for large-scale protein expression as described (Homann et al., 2001). Sf9 cavity using a heparinized glass capillary. A blood smear was prepared and
cell pellets from 5-liter cultures were resuspended in 50 ml of ice-cold lysis stained with Wright and Giemsa (Sigma). Manual white blood cell counts
buffer (25 mM Tris-HCl [pH 7.5], 2 mM EDTA, 1% NP-40, 1 mM DTT, 1 mM were performed and a sample of blood was analyzed using the ADIVA 120
PMSF), stirred on ice for 15 min, and then centrifuged at 5000 rpm for 20 Hematology system (Bayer) for total and differential blood counts. Anesthesia
min. The centrifuged cell lysate was then loaded onto a 2 ml glutathione- was achieved using Methoxyfluroane (Australia) and then animals were sacri-
sepharose column (Pharmacia) and washed three times with 10 ml of 25 ficed by cervical dislocation. The spleen, liver, heart, lungs, intestine, hind
mM Tris-HCl [pH 7.5], 2 mM EDTA, 1 mM DTT, and 200 mM NaCl. The limb bones, and kidneys were examined and collected. The spleen weight
GST-tagged protein was eluted by 10 applications (1 ml each) of 25 mM and any other unusual observations were recorded. Samples of all organs
Tris-HCl [pH 7.5], 10 mM reduced-glutathione, 100 mM NaCl, 1 mM DTT, were stored in 10% Formalin/PBS solution (Sigma). A single cell suspension
and 10% Glycerol, and stored at 70
C. Protein tyrosine kinase assays from the spleen and bone marrow was prepared and stored in 10% dimethyl-
using the purified GST-FLT3 were carried out in a final volume of 30 l sulphoxide/90% Fetal Calf Serum.
containing 200–1800 ng of enzyme protein (depending upon the specific Histopathology
activity), 20 mM Tris-HCl [pH 7.6], 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, Murine tissues were fixed for at least 72 hr in 10% neutral buffered formalin
10 M Na3VO4, 3 g/ml poly (Glu, Tyr) 4:1, 1% DMSO, 8.0 M ATP, and (Sigma), dehydrated in alcohol, cleared in xylene, and infiltrated with paraffin
0.1 Ci [33P] ATP. The activity was assayed in the presence or absence of on an automated processor (Leica). 4 micron-thick tissue sections from
PKC412 by measuring the incorporation of 33P from [33P] ATP into the poly paraffin embedded tissue blocks were placed on charged slides, and depara-
(Glu, Tyr) substrate as described (Homann et al., 2001). Assay (30 l) were ffinized in xylene, rehydrated through graded alcohol solutions, and stained
carried out in 96-well plates at RT for 20 min, and terminated by the addition
with hematoxylin and eosin.
of 20 l of 125 mM EDTA. 40 l of the reaction mixture was transferred
onto Immobilon-PVDF membrane (Millipore, Bedford, MA) previously soaked
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